1. Welcome to the All Things Male Forum. Please sign up and join the conversation. It's free!

Effect Of Testosterone On Fgf2, Mrf4 And Myostatin In Hypogonadotropic Hypogonadism:...

Discussion in 'Scientific Studies' started by pubmed: testosterone, Jan 11, 2019.

  1. Effect of testosterone on FGF2, MRF4 and myostatin in hypogonadotropic hypogonadism: relevance to muscle growth.

    J Clin Endocrinol Metab. 2019 Jan 09;:

    Authors: Ghanim H, Dhindsa S, Batra M, Green K, Abuaysheh S, Kuhadiya ND, Makdissi A, Chaudhuri A, Dandona P

    Abstract
    Context: Basic Fibroblast growth factor (FGF2) is an important stimulatory modulator of satellite cells in the skeletal muscle, which play a cardinal role in muscle growth and repair.
    Objective: We evaluated whether the skeletal muscle expression of FGF2 and muscle growth and differentiation factors are reduced in patients with hypogonadotropic hypogonadism (HH), and whether testosterone replacement therapy results in their restoration.
    Design: This is a secondary analysis of a previously completed trial of testosterone replacement in men with type 2 diabetes and HH.
    Setting: Clinical Research Center at University.
    Patients: Twenty-two men with HH and 20 eugonadal men were compared at baseline.
    Interventions: Twelve men with HH were treated with intramuscular injections of 200mg testosterone every 2 weeks for 22 weeks, while 10 men received placebo injections. Quadriceps muscle biopsies and blood samples were obtained prior to and after testosterone therapy.
    Outcome Measures and Results: The expression of FGF2 and FGFR2 in skeletal muscle of HH men was significantly lower than that in eugonadal men by 57% and 39%, respectively (p<0.05). Following 22 weeks of testosterone, the expression of FGF2 increased, while that of MRF4 and myostatin decreased significantly. There was no change in expression of FGFR2, myogenin and MyoD in the skeletal muscle. Plasma FGF2 and IGF-1 concentrations increased following TRT.
    Conclusions: These data show for the first time that testosterone is a major modulator of FGF2, MRF4 and myostatin expression in skeletal muscle. These effects may contribute to the increase in muscle mass following testosterone therapy.

    PMID: 30629183 [PubMed - as supplied by publisher]

    Continue reading...
     

Share This Page

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.